Welcome to our dedicated page for Cerus news (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus stock.
Cerus Corporation develops and supplies blood-safety technologies and pathogen-protected blood components for blood centers and hospitals. Its recurring news centers on the INTERCEPT Blood System for platelets and plasma, the U.S. INTERCEPT Blood System for Cryoprecipitation used to produce INTERCEPT Fibrinogen Complex, and the company’s red blood cell pathogen-reduction program.
Company updates commonly cover product revenue, gross margin trends, revenue guidance, government contract activity, international supply agreements, clinical studies involving pathogen-inactivated platelets, regulatory and pipeline developments, healthcare conference participation, and governance changes. Commercial disclosures often emphasize demand for INTERCEPT Fibrinogen Complex and adoption of pathogen inactivation technologies by blood establishments in the United States, Europe and other markets.
Cerus (Nasdaq:CERS) will highlight new data on the INTERCEPT Blood System at the 39th International ISBT Congress in Kuala Lumpur from June 20–24, 2026.
The company is sponsoring a lunch symposium and multiple abstracts on blood safety, pathogen inactivation, platelet shelf-life, and operational efficiency.
Cerus (Nasdaq:CERS) closed a new debt facility with MidCap Financial totaling up to $110 million, comprising a 5-year term loan and a 5-year asset-backed revolving loan.
The refinancing retires a $65 million term loan, is expected to cut annual cash interest by up to $3.5 million, and reduces the outstanding term loan balance by about $30 million.
Bradley L. Radoff, a significant Cerus (NASDAQ:CERS) shareholder, plans to withhold votes from Chair and CEO William Greenman and director Ann Lucena at the June 2, 2026 annual meeting.
He cites a 10-year total shareholder return of (50.8%), share count growth from about 101.7 million to 200.3 million, ongoing net losses, repeated equity share increases despite notable investor opposition, a classified board structure, and plans to move Greenman to Executive Chair. Radoff also questions approximately $150 million of operating expenses and the company’s strategic focus.
Cerus (Nasdaq: CERS) reported Q1 2026 total revenue $59.9M (up 23% YoY) and product revenue $53.7M (up 24% YoY). The company raised full‑year product revenue guidance to $227M–$231M, including IFC revenue $22M–$24M. Cash and short‑term investments were $80.4M at March 31, 2026. Net loss narrowed to $1.6M ($0.01 per share) and adjusted EBITDA was $4.0M. Management transition: COO Vivek Jayaraman named CEO effective July 1, 2026; current CEO becomes executive chairman.
Cerus (Nasdaq: CERS) signed a new four-year supply agreement with Établissement Français du Sang (EFS) for the INTERCEPT Blood System covering platelets, plasma and the next-generation INT200 LED illumination device.
The agreement continues EFS's nationwide use of INTERCEPT (platelets since 2006; nationwide rollout 2017) and supports distribution to ~330,000 platelet units annually across 13 regional centers and overseas territories.
Cerus Corporation (Nasdaq: CERS) will release first quarter 2026 financial results on April 30, 2026 after market close and will host a conference call and webcast at 4:30 P.M. ET that day.
According to the company, management will discuss financial results, provide a general business overview and outlook, and presentation slides and a replay will be available on the Cerus Investor Relations website through May 21, 2026.
Cerus (Nasdaq: CERS) named Vivek Jayaraman president and chief executive officer, effective July 1, 2026, with William “Obi” Greenman moving to executive chairman.
Mr. Jayaraman, Cerus COO since 2020, grew product revenue from under $40M to over $200M in 2025; Cerus has product sales in 40+ countries and four FDA approvals in the past decade.
Cerus (Nasdaq: CERS) reported 2025 total revenue of $233.8 million (+16% YoY) and product revenue of $206.1 million (+14% YoY).
Key items: IFC revenue rose ~80% to $16.7 million, GAAP net loss narrowed to $15.6 million, non-GAAP adjusted EBITDA was $9.5 million, cash and short-term investments were $82.9 million, and 2026 product revenue guidance is $224–228 million.
Cerus Corporation (Nasdaq: CERS) said company management will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 10:30 a.m. ET. A live webcast will be available on the company Investor Relations site, with a replay accessible for 90 days.
Cerus Corporation (Nasdaq: CERS) will release fourth quarter and full-year 2025 financial results on March 2, 2026 after market close.
The company will host a conference call and webcast at 4:30 P.M. ET to discuss results, outlook, and provide presentation slides; a replay will be available through March 23, 2026.